Author/Authors :
Brašic, James Robert Russell H. Morgan Department of Radiology and Radiological Science - Johns Hopkins University School of Medicine - Baltimore, Maryland, United States , Mathur, Anil K Russell H. Morgan Department of Radiology and Radiological Science - Johns Hopkins University School of Medicine - Baltimore, Maryland, United States , Budimirovic, Dejan B Department of Psychiatry and Behavioral Sciences-Child Psychiatry - Kennedy Krieger Institute - Johns Hopkins University School of Medicine, Baltimore, Maryland, United
Abstract :
Promising therapeutic agents for the symptoms in animal models of fragile X syndrome (FXS) have not resulted in similar advances in clinical trials of humans with FXS due to the dearth of tools to quantify their key cognitive and behavioral outcome measures with optimal validity and reliability. Therefore, experts strongly recommended an e ort to develop and implement use of biomarkers in unfolding clinical trials in FXS. Molecular imaging provides a spectrum of agents to serve as biomarkers to confirm that humans with FXS exhibit the molecular abnormalities of animal models of FXS. Thus, molecular imaging provides the mechanism to estab-lish target engagement in humans for clinical trials of novel agents for FXS.
Keywords :
Neurotransmission , Positron Emission Tomography , Receptors , Single-Photon Emission Computed Tomography , Transporters
